Arena Pharmaceuticals (ARNA) Flips Positive on FDA Staff Questions
Tweet
Share
E-mail
Get Alerts ARNA Hot Sheet
Join SI Premium – FREE
After originally trading down on FDA staff questions ahead of the May 10 FDA AdCom for weight loss drug Locaserin, Arena Pharmaceuticals (Nasdaq: ARNA) is now up 12 percent.
In October 2011, Arena and partner Eisai Inc. received a Complete Response Letter (CRL) from the FDA on Locaserin. In December 2011, the comapny resubmitted the lorcaserin NDA and the he FDA accepted the resubmission for and assigned a PDUFA date of June 27th.
It promises to be a whipsaw day for Arena.
Link
In October 2011, Arena and partner Eisai Inc. received a Complete Response Letter (CRL) from the FDA on Locaserin. In December 2011, the comapny resubmitted the lorcaserin NDA and the he FDA accepted the resubmission for and assigned a PDUFA date of June 27th.
It promises to be a whipsaw day for Arena.
Link
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA: issues early alert on Abiomed heart pump controller purge cassette issue
- Anthropic: launching research preview of model hardware standard
- Chevron Close To A Deal To Expand Operations In Venezuela - WSJ
Create E-mail Alert Related Categories
FDA, Momentum Movers, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
